{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:14:33Z","timestamp":1788426873163,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension in haemodialysis is common, prognostically important, and difficult to manage because blood pressure measurement is often imprecise, extracellular volume is dynamic, and low blood pressure may reflect heart failure, frailty, impaired forward flow, autonomic dysfunction, or excessive ultrafiltration rather than therapeutic success. Contemporary evidence supports ambulatory blood pressure monitoring as the reference standard and home blood pressure monitoring as the most practical longitudinal method, while accepted targets remain unsettled. Treatment should begin with standardised assessment of interdialytic blood pressure burden and sodium-volume control through dietary sodium restriction, dialysate sodium consideration, dry-weight reassessment, ultrafiltration management, and adequate treatment time. This sequence helps distinguish true treatment resistance from pseudoresistance caused by dialysis-unit measurement artefacts, volume excess, short treatment time, sodium burden, medication nonadherence, poorly timed dosing, or dialytic drug removal. Once persistent hypertension is confirmed despite sodium-volume and dry-weight-oriented care, pharmacotherapy becomes necessary. Beta-blockers have the strongest outcome-linked support in haemodialysis, whereas calcium channel blockers (CCBs) are practical complementary agents, and conventional renin-angiotensin system (RAS) blockade is best reserved for selected indications. Mineralocorticoid receptor antagonists (MRAs) should be considered cautiously because recent large dialysis trials and updated meta-analytic evidence have not confirmed clear cardiovascular benefit. Sacubitril\/valsartan is biologically plausible when hypertension coexists with heart failure with reduced ejection fraction, left ventricular dysfunction, recurrent congestion, or high natriuretic peptide burden. However, it should be framed as a promising but not yet established selective option rather than routine escalation therapy.<\/jats:p>","DOI":"10.1093\/joneph\/aajag181","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:37:03Z","timestamp":1782214623000},"source":"Crossref","is-referenced-by-count":0,"title":["Blood pressure in haemodialysis: measurement, volume control and drug selection"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6851-1542","authenticated-orcid":false,"given":"Yoshitaka","family":"Furuto","sequence":"first","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo , Tokyo \u00a0","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo , Tokyo \u00a0","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo , Tokyo \u00a0","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo , Tokyo \u00a0","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo , Tokyo \u00a0","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026090304275423800_aajag181-B1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.kint.2020.01.046","article-title":"Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Flythe","year":"2020","journal-title":"Kidney Int"},{"key":"2026090304275423800_aajag181-B2","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1161\/HYP.0000000000000230","article-title":"Hypertension in patients treated with in-center maintenance hemodialysis: current evidence and future opportunities: a scientific statement from the American Heart Association","volume":"80","author":"Bansal","year":"2023","journal-title":"Hypertension"},{"key":"2026090304275423800_aajag181-B3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12882-025-04451-2","article-title":"Management of blood pressure in adults, children and young people on dialysis: UK Kidney Association clinical practice guideline","volume":"26","author":"Doulton","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026090304275423800_aajag181-B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40885-023-00240-x","article-title":"Diagnosis and treatment of hypertension in dialysis patients: a systematic review","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"key":"2026090304275423800_aajag181-B5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrneph.2016.129","article-title":"Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis","volume":"12","author":"Georgianos","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2026090304275423800_aajag181-B6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/ki.2009.469","article-title":"Blood pressure in chronic kidney disease stage 5D: report from a Kidney Disease: Improving Global Outcomes controversies conference","volume":"77","author":"Levin","year":"2010","journal-title":"Kidney Int"},{"key":"2026090304275423800_aajag181-B7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1681\/ASN.0000000000000315","article-title":"Resistant hypertension in dialysis: epidemiology, diagnosis, and management","volume":"35","author":"Georgianos","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026090304275423800_aajag181-B8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000206698","article-title":"Home blood pressure measurements for managing hypertension in hemodialysis patients","volume":"30","author":"Agarwal","year":"2009","journal-title":"Am J Nephrol"},{"key":"2026090304275423800_aajag181-B9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.2215\/CJN.02250507","article-title":"Home blood pressures are of greater prognostic value than hemodialysis unit recordings","volume":"2","author":"Alborzi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090304275423800_aajag181-B10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1161\/HYPERTENSIONAHA.109.144899","article-title":"Blood pressure and mortality among hemodialysis patients","volume":"55","author":"Agarwal","year":"2010","journal-title":"Hypertension"},{"key":"2026090304275423800_aajag181-B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/j.ajkd.2020.06.014","article-title":"Treating home versus predialysis blood pressure among in-center hemodialysis patients: a pilot randomized trial","volume":"77","author":"Bansal","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026090304275423800_aajag181-B12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/1744-9987.14142","article-title":"The association of home blood pressure with all-cause mortality in hemodialysis patients: a prospective observational study","volume":"28","author":"Kontogiorgos","year":"2024","journal-title":"Ther Apher Dial"},{"key":"2026090304275423800_aajag181-B13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.108.125674","article-title":"Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"2026090304275423800_aajag181-B14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2215\/CJN.01760210","article-title":"Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients","volume":"5","author":"Agarwal","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090304275423800_aajag181-B15","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1093\/ndt\/gfq210","article-title":"Intradialytic hypertension is a marker of volume excess","volume":"25","author":"Agarwal","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/sdi.12624","article-title":"Setting the dry weight and its cardiovascular implications","volume":"30","author":"Sinha","year":"2017","journal-title":"Semin Dial"},{"key":"2026090304275423800_aajag181-B17","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/ndt\/gfs597","article-title":"Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure","volume":"28","author":"Tandon","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-024-01320-5","article-title":"Intradialytic hypertension in maintenance hemodialysis","volume":"27","author":"Iatridi","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2026090304275423800_aajag181-B19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B20","doi-asserted-by":"publisher","first-page":"ii10","DOI":"10.1093\/ckj\/sfaf285","article-title":"2025 update on resistant hypertension in CKD: where do we stand and where do we go?","volume":"18","author":"Schmieder","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026090304275423800_aajag181-B21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomized controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"2026090304275423800_aajag181-B22","doi-asserted-by":"publisher","first-page":"ii47","DOI":"10.1093\/ckj\/sfaf315","article-title":"Choosing the right antihypertensive drug to avoid intradialytic hypotension","volume":"18","author":"Zoccali","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026090304275423800_aajag181-B23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/ndt\/gfu029","article-title":"Cardiovascular protection by beta-blockade in hypertensive haemodialysis patients: the Hypertension in Haemodialysis Patients treated with Atenolol or Lisinopril (HDPAL) trial","volume":"29","author":"Zoccali","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100460","article-title":"Beta-blocker use and cardiovascular outcomes in hemodialysis: a systematic review","volume":"4","author":"Tella","year":"2022","journal-title":"Kidney Med"},{"key":"2026090304275423800_aajag181-B26","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s11255-024-03973-2","article-title":"Beta-blocker efficacy for intra- and interdialytic hypertension patients: a systematic review and meta-analysis","volume":"56","author":"Hartono","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"2026090304275423800_aajag181-B27","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B28","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis: a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026090304275423800_aajag181-B30","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026090304275423800_aajag181-B31","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"2026090304275423800_aajag181-B32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"key":"2026090304275423800_aajag181-B33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet"},{"key":"2026090304275423800_aajag181-B34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(25)01153-5","article-title":"Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"406","author":"Pyne","year":"2025","journal-title":"Lancet"},{"key":"2026090304275423800_aajag181-B35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000545195","article-title":"Sacubitril-valsartan lowers blood pressure in patients on dialysis: a randomized controlled multicenter study","volume":"11","author":"Lin","year":"2025","journal-title":"Kidney Dis (Basel)"},{"key":"2026090304275423800_aajag181-B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29237","article-title":"Sacubitril-valsartan in patients requiring hemodialysis","volume":"7","author":"Le","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026090304275423800_aajag181-B37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ejhf.3454","article-title":"Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: a systematic review and meta-analysis","volume":"27","author":"Nguyen","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026090304275423800_aajag181-B38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10557-023-07481-w","article-title":"Sacubitril\/valsartan in dialysis patients: update on current perspectives","volume":"39","author":"Spatola","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026090304275423800_aajag181-B39","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis","volume":"45","author":"Ding","year":"2023","journal-title":"Ren Fail"},{"key":"2026090304275423800_aajag181-B40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cardfail.2022.09.013","article-title":"Managing heart failure in patients on dialysis: state-of-the-art review","volume":"29","author":"Khan","year":"2023","journal-title":"J Card Fail"},{"key":"2026090304275423800_aajag181-B41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.31083\/j.rcm2506232","article-title":"Management of chronic heart failure in dialysis patients: a challenging but rewarding path","volume":"25","author":"Guo","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"2026090304275423800_aajag181-B42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.kint.2017.01.038","article-title":"Blood pressure targets for hemodialysis patients","volume":"92","author":"Turner","year":"2017","journal-title":"Kidney Int"},{"key":"2026090304275423800_aajag181-B43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.23876\/j.krcp.22.241","article-title":"Target blood pressure in Korean hemodialysis patients for optimal survival","volume":"44","author":"Kim","year":"2025","journal-title":"Kidney Res Clin Pract"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag181\/70935302\/aajag181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag181\/70935302\/aajag181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:27:57Z","timestamp":1788424077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article\/doi\/10.1093\/joneph\/aajag181\/8780932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag181","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"aajag181"}}